U.S./EMEA Special Situations: Covis Likely to Face a Second Round of Restructuring, Moody’s Warns in Knocking Rating Down to Caa3 from CaaK
Covis Pharma's ongoing EBITDA reductions have led to weak cash flow since the company's restructuring…
Siobhan HodsonDecember 28, 2023
